Jonathan W. Ayers - May 28, 2021 Form 4 Insider Report for IDEXX LABORATORIES INC /DE (IDXX)

Role
Director
Signature
/s/ Lily J. Lu, Attorney-in-Fact for Jonathan W. Ayers
Stock symbol
IDXX
Transactions as of
May 28, 2021
Transactions value $
-$4,566,540
Form type
4
Date filed
6/1/2021, 06:00 PM
Previous filing
May 26, 2021
Next filing
Jan 4, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IDXX Common Stock Gift $0 -9K -1.38% $0.00 645K May 12, 2021 Direct
transaction IDXX Common Stock Options Exercise $752K +9.46K +1.47% $79.54* 654K May 28, 2021 Direct
transaction IDXX Common Stock Sale -$1.39M -2.48K -0.38% $560.38 652K May 28, 2021 Direct F1
transaction IDXX Common Stock Sale -$934K -1.66K -0.26% $561.57 650K May 28, 2021 Direct F2
transaction IDXX Common Stock Sale -$1.46M -2.6K -0.4% $562.48 647K May 28, 2021 Direct F3
transaction IDXX Common Stock Sale -$789K -1.4K -0.22% $563.82 646K May 28, 2021 Direct F4
transaction IDXX Common Stock Sale -$742K -1.32K -0.2% $564.60 645K May 28, 2021 Direct F5
holding IDXX Common Stock 10K May 28, 2021 by Ayers Family Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IDXX Non-Qualified Stock Option (right-to-buy) Options Exercise -9.46K -7.57% 116K May 28, 2021 Common Stock 9.46K $79.54 Direct F6, F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the weighted average price of the shares sold ranging from a low of $560.00 to a high of $561.00 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F2 Represents the weighted average price of the shares sold ranging from a low of $561.005 to a high of $561.92 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F3 Represents the weighted average price of the shares sold ranging from a low of $562.02 to a high of $563.02 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F4 Represents the weighted average price of the shares sold ranging from a low of $563.03 to a high of $564.03 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F5 Represents the weighted average price of the shares sold ranging from a low of $564.11 to a high of $564.93 per share. The undersigned undertakes, upon a request by the Commission staff, the issuer or a security holder of the issuer, to provide full information regarding the number of shares purchased at each separate price.
F6 Grant of option to buy 74,316 shares of IDEXX Laboratories, Inc. common stock that became exercisable in five equal annual installments beginning on February 14, 2016 without giving effect to the 2-for-1 stock split of IDEXX Laboratories, Inc. common stock that occurred on June 15, 2015 (the "Stock Split"). The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
F7 Not applicable.